Back

Ventricular tachycardia burden in heart failure with reduced ejection fraction - can we rely on optimized medical therapy

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Miscellaneous clinical studies in heart failure (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Fran Rode

University Hospital Dubrava, Zagreb (Croatia)

7 More presentations in this session

Presentation thumbnail
Masked hypotension in patients with heart failure
Doctor Z. Qiu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
Relationship between chronic obstructive pulmonary disease and heart failure hospitalization in patients with atrial fibrillation: the Fushimi AF Registry
Doctor M. Ishii (Kyoto, JP)
Abstract Slides Video
Presentation thumbnail
Associations between biomarkers and P-wave indices in patients with heart failure
Doctor Z. Nezami (Malmo, SE)
Abstract Slides Video
Presentation thumbnail
Electrocardiographic markers of depolarization and repolarization in lead V1 predict right ventricular dysfunction in patients with heart failure
Doctor M. Moldovan (Cluj Napoca, RO)
Abstract Slides Video
Presentation thumbnail
Twelve-lead electrocardiography-based artificial intelligence predicts the upcoming future of patients with heart failure with mildly reduced ejection fraction
Assistant Professor D. Kim (Incheon, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Miscellaneous clinical studies in heart failure (1)

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Retrospective review of primary prevention implantable cardiac defibrillator insertions for heart failure with reduced ejection fraction
thumbnail
Congress Presentation
Implantable cardioverter-defibrillator therapies in primary prevention are not decreased in a contemporary cohort: insights from long-term follow-up
thumbnail
Congress Presentation
Effect of improving utilization of guideline-directed medical therapy for heart failure.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources